GlassScriptPhysician profile
Susan K Morgan
NPI 1366425209
$2,059.71
in general payments reported to CMS, 2019-2025
34 companies · $2,005 in 2025
The $2,005 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.37 · 2024: $42.18 · 2025: $2,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,947 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.39 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $182.21 | 2025 | Enhertu, Imfinzi, Calquence |
| Novartis Pharmaceuticals Corporation | $161.48 | 2024-2025 | |
| Beone Medicines USA, INC. | $140.86 | 2025 | Brukinsa, Tevimbra |
| Exelixis INC. | $120.61 | 2025 | Cabometyx |
| Daiichi Sankyo INC. | $105.87 | 2025 | Datroway, Enhertu |
| Incyte Corporation | $102.80 | 2025 | Monjuvi, Zynyz, Jakafi |
| Abbvie INC. | $94.21 | 2025 | |
| Merck Sharp & Dohme LLC | $94.11 | 2025 | Keytruda, Keytruda Qlex |
| Janssen Biotech, INC. | $85.98 | 2025 | Rybrevant, Erleada, Talvey |
| Astellas Pharma US INC | $85.42 | 2019-2025 | Vyloy |
| E.R. Squibb & Sons, L.L.C. | $85.35 | 2025 | Opdualag, Opdivo |
| Pfizer INC. | $67.40 | 2025 | |
| Celgene Corporation | $57.91 | 2025 | Opdualag |
| Sobi, INC | $56.06 | 2025 | |
| Genentech USA, INC. | $56.06 | 2024-2025 | Tecentriq, Polivy, Itovebi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $47.28 | 2025 | Onivyde |
| Glaxosmithkline, LLC. | $47.15 | 2025 | Ojjaara, Blenrep |
| Taiho Oncology, INC. | $46.78 | 2025 | |
| Gilead Sciences, INC. | $46.35 | 2025 | Trodelvy |
| Array Biopharma INC | $43.87 | 2025 | Braftovi, Mektovi, Xalkori |
| Jazz Pharmaceuticals INC. | $43.10 | 2025 | |
| Karyopharm Therapeutics INC. | $39.67 | 2025 | Xpovio |
| Tersera Therapeutics LLC | $30.85 | 2025 | Zoladex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.82 | 2025 | |
| Beigene USA, INC. | $24.23 | 2025 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $23.23 | 2025 | Fruzaqla |
| Syndax Pharmaceuticals, INC. | $20.27 | 2025 | |
| Dendreon Pharmaceuticals LLC | $20.05 | 2025 | Provenge |
| Puma Biotechnology, INC. | $18.74 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.68 | 2025 | |
| Alexion Pharmaceuticals, INC. | $18.02 | 2025 | Ultomiris |
| Genzyme Corporation | $17.11 | 2025 | |
| Aveo Pharmaceuticals, INC. | $16.44 | 2025 | |
| Genmab U.S., INC. | $14.74 | 2025 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.